Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
← catalyst calendarNCT07542314 · readout in 224 d
Sponsored by Sarepta Therapeutics, Inc. (industry) · SRPT — their whole pipeline →.
Phase
Phase 4
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
20estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-31 | estimated | When the study began enrolling |
| Primary completion | 2027-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Duchenne Muscular Dystrophy
Interventions
- Drug: ELEVIDYS — also filed as Delandistrogene moxeparvovec-rokl, SRP-9001
- Drug: Sirolimus
- Drug: Glucocorticoids
- Drug: Antibiotics
Primary outcome
what the primary-completion date above is the date OFCohort 1: Number of Participants with ALI
measured 12 weeks
Permalink · SRPT's whole pipeline · Catalyst calendar · Every registered study · What changed